3results about How to "Few adverse effect" patented technology

This invention provides an interleukin-31 (IL-31) production inhibitor and a pharmaceutical composition comprising the inhibitor. The invention also provides a novel compound useful as an active ingredient for an IL-31 production inhibitor. These comprise a compound represented by the following formula (1) or a salt thereof as an active ingredient: wherein A is a -NH-N=C(R1)- group, a divalent N-containing 5-membered heterocyclic group, or a -NH-CO- group, wherein R1 is a hydrogen atom or a C1-4 alkyl group, B is the same or different and is a C1-6 alkyl group optionally having one hydroxyl group, a mono or di(C1-6 alkyl)amino group optionally having one hydroxyl group, a halogen atom, a halo C1-6 alkyl group, a C2-6 alkynylene group, or a carboxy group, wherein at least one C1-6 alkyl group in the mono or di (C1-6 alkyl) amino group is optionally attached to a carbon atom adjacent to a carbon atom in the phenyl group to which it is attached, to form a 5- to 6-membered ring, and n is an integer of 1 to 5.

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.